After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.

Beam Therapeutics’ experimental gene-editing therapy for sickle cell disease now has its first cut of patient data showing signs of treating the rare blood disorder in a way that could differentiate ...

Add Yahoo as a preferred source to see more of our stories on Google. Futuristic 3D cubes showing DNA base pairs and a double helix. (JuSun via Getty Images) This story was originally published on ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the top gene therapy stocks to buy according to hedge funds. On February 25, ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...

Beam Therapeutics Inc. buy thesis: base-editing gene therapy leaders, risto-cel & BEAM-302 catalysts, strong cash runway.

On Tuesday, Beam Therapeutics Inc. (NASDAQ:BEAM) announced that 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 trial of BEAM-101, an investigational genetically modified cell ...

Beam Therapeutics BEAM announced that the FDA has granted an orphan drug designation to its investigational genome-editing candidate, BEAM-101, for the treatment of sickle cell disease (SCD), an ...

Blue Shield of California is the latest major insurer to scale back coverage for proton beam therapy for early stage prostate cancer, according to a Wall Street Journal report. In letters sent this ...

ROCHESTER — When Derek Gerlach, then 10 years old, was diagnosed with stage 4 brain cancer in November 2018, his treatment began almost immediately. Within a month, Derek underwent surgery to remove ...